The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Anti-tumor Drug-Global Market Insights and Sales Trends 2025
Synopsis
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
The global Anti-tumor Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Anti-tumor Drug in various end use industries. The expanding demands from the Alkylating Agents, Anti-Metabolism Drugs, Platinum Antineoplastic Agents and Anthracycline Antitumor Drugs, are propelling Anti-tumor Drug market. Cytotoxic Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-cytotoxic Drugs segment is estimated at % CAGR for the next seven-year period.
In China, Anti-tumor Drug key players include AstraZeneca, Merck & Co., Roche, Celgene, Johnson & Johnson, etc.
United States is the largest market, followed by Japan, and Europe.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Anti-tumor Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Anti-tumor Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Anti-tumor Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Anti-tumor Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Anti-tumor Drug covered in this report include Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda and Eli Lilly, etc.
The global Anti-tumor Drug market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
Novartis
Celgene
Bristol-Myers Squibb
Amgen
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co
Sanofi
Bayer
Biogen Idec
Eisai
Teva
Otsuka
Global Anti-tumor Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Anti-tumor Drug market, Segment by Type:
Cytotoxic Drugs
Non-cytotoxic Drugs
Global Anti-tumor Drug market, by Application
Alkylating Agents
Anti-Metabolism Drugs
Platinum Antineoplastic Agents
Anthracycline Antitumor Drugs
Microtubule Stabilizer
Endocrine Therapy Drugs
Immunotherapy Drugs
Gene Therapy Drugs
Targeted Antineoplastic Drugs
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Anti-tumor Drug companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
The global Anti-tumor Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Anti-tumor Drug in various end use industries. The expanding demands from the Alkylating Agents, Anti-Metabolism Drugs, Platinum Antineoplastic Agents and Anthracycline Antitumor Drugs, are propelling Anti-tumor Drug market. Cytotoxic Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Non-cytotoxic Drugs segment is estimated at % CAGR for the next seven-year period.
In China, Anti-tumor Drug key players include AstraZeneca, Merck & Co., Roche, Celgene, Johnson & Johnson, etc.
United States is the largest market, followed by Japan, and Europe.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Anti-tumor Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Anti-tumor Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Anti-tumor Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Anti-tumor Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Anti-tumor Drug covered in this report include Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda and Eli Lilly, etc.
The global Anti-tumor Drug market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
Novartis
Celgene
Bristol-Myers Squibb
Amgen
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co
Sanofi
Bayer
Biogen Idec
Eisai
Teva
Otsuka
Global Anti-tumor Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Anti-tumor Drug market, Segment by Type:
Cytotoxic Drugs
Non-cytotoxic Drugs
Global Anti-tumor Drug market, by Application
Alkylating Agents
Anti-Metabolism Drugs
Platinum Antineoplastic Agents
Anthracycline Antitumor Drugs
Microtubule Stabilizer
Endocrine Therapy Drugs
Immunotherapy Drugs
Gene Therapy Drugs
Targeted Antineoplastic Drugs
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Anti-tumor Drug companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Anti-tumor Drug
1.1 Anti-tumor Drug Market Overview
1.1.1 Anti-tumor Drug Product Scope
1.1.2 Anti-tumor Drug Market Status and Outlook
1.2 Global Anti-tumor Drug Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Anti-tumor Drug Market Size by Region (2018-2029)
1.4 Global Anti-tumor Drug Historic Market Size by Region (2018-2023)
1.5 Global Anti-tumor Drug Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Anti-tumor Drug Market Size (2018-2029)
1.6.1 North America Anti-tumor Drug Market Size (2018-2029)
1.6.2 Europe Anti-tumor Drug Market Size (2018-2029)
1.6.3 Asia-Pacific Anti-tumor Drug Market Size (2018-2029)
1.6.4 Latin America Anti-tumor Drug Market Size (2018-2029)
1.6.5 Middle East & Africa Anti-tumor Drug Market Size (2018-2029)
2 Anti-tumor Drug Market by Type
2.1 Introduction
2.1.1 Cytotoxic Drugs
2.1.2 Non-cytotoxic Drugs
2.2 Global Anti-tumor Drug Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Anti-tumor Drug Historic Market Size by Type (2018-2023)
2.2.2 Global Anti-tumor Drug Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Anti-tumor Drug Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Anti-tumor Drug Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Anti-tumor Drug Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Anti-tumor Drug Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Anti-tumor Drug Revenue Breakdown by Type (2018-2029)
3 Anti-tumor Drug Market Overview by Application
3.1 Introduction
3.1.1 Alkylating Agents
3.1.2 Anti-Metabolism Drugs
3.1.3 Platinum Antineoplastic Agents
3.1.4 Anthracycline Antitumor Drugs
3.1.5 Microtubule Stabilizer
3.1.6 Endocrine Therapy Drugs
3.1.7 Immunotherapy Drugs
3.1.8 Gene Therapy Drugs
3.1.9 Targeted Antineoplastic Drugs
3.2 Global Anti-tumor Drug Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Anti-tumor Drug Historic Market Size by Application (2018-2023)
3.2.2 Global Anti-tumor Drug Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Anti-tumor Drug Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Anti-tumor Drug Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Anti-tumor Drug Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Anti-tumor Drug Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Anti-tumor Drug Revenue Breakdown by Application (2018-2029)
4 Anti-tumor Drug Competition Analysis by Players
4.1 Global Anti-tumor Drug Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Anti-tumor Drug as of 2022)
4.3 Date of Key Players Enter into Anti-tumor Drug Market
4.4 Global Top Players Anti-tumor Drug Headquarters and Area Served
4.5 Key Players Anti-tumor Drug Product Solution and Service
4.6 Competitive Status
4.6.1 Anti-tumor Drug Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Roche
5.1.1 Roche Profile
5.1.2 Roche Main Business
5.1.3 Roche Anti-tumor Drug Products, Services and Solutions
5.1.4 Roche Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.1.5 Roche Recent Developments
5.2 Novartis
5.2.1 Novartis Profile
5.2.2 Novartis Main Business
5.2.3 Novartis Anti-tumor Drug Products, Services and Solutions
5.2.4 Novartis Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.2.5 Novartis Recent Developments
5.3 Celgene
5.3.1 Celgene Profile
5.3.2 Celgene Main Business
5.3.3 Celgene Anti-tumor Drug Products, Services and Solutions
5.3.4 Celgene Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.3.5 Bristol-Myers Squibb Recent Developments
5.4 Bristol-Myers Squibb
5.4.1 Bristol-Myers Squibb Profile
5.4.2 Bristol-Myers Squibb Main Business
5.4.3 Bristol-Myers Squibb Anti-tumor Drug Products, Services and Solutions
5.4.4 Bristol-Myers Squibb Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.4.5 Bristol-Myers Squibb Recent Developments
5.5 Amgen
5.5.1 Amgen Profile
5.5.2 Amgen Main Business
5.5.3 Amgen Anti-tumor Drug Products, Services and Solutions
5.5.4 Amgen Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.5.5 Amgen Recent Developments
5.6 Johnson & Johnson
5.6.1 Johnson & Johnson Profile
5.6.2 Johnson & Johnson Main Business
5.6.3 Johnson & Johnson Anti-tumor Drug Products, Services and Solutions
5.6.4 Johnson & Johnson Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.6.5 Johnson & Johnson Recent Developments
5.7 Pfizer
5.7.1 Pfizer Profile
5.7.2 Pfizer Main Business
5.7.3 Pfizer Anti-tumor Drug Products, Services and Solutions
5.7.4 Pfizer Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.7.5 Pfizer Recent Developments
5.8 Takeda
5.8.1 Takeda Profile
5.8.2 Takeda Main Business
5.8.3 Takeda Anti-tumor Drug Products, Services and Solutions
5.8.4 Takeda Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.8.5 Takeda Recent Developments
5.9 Eli Lilly
5.9.1 Eli Lilly Profile
5.9.2 Eli Lilly Main Business
5.9.3 Eli Lilly Anti-tumor Drug Products, Services and Solutions
5.9.4 Eli Lilly Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.9.5 Eli Lilly Recent Developments
5.10 AstraZeneca
5.10.1 AstraZeneca Profile
5.10.2 AstraZeneca Main Business
5.10.3 AstraZeneca Anti-tumor Drug Products, Services and Solutions
5.10.4 AstraZeneca Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.10.5 AstraZeneca Recent Developments
5.11 Astellas
5.11.1 Astellas Profile
5.11.2 Astellas Main Business
5.11.3 Astellas Anti-tumor Drug Products, Services and Solutions
5.11.4 Astellas Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.11.5 Astellas Recent Developments
5.12 Merck & Co
5.12.1 Merck & Co Profile
5.12.2 Merck & Co Main Business
5.12.3 Merck & Co Anti-tumor Drug Products, Services and Solutions
5.12.4 Merck & Co Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.12.5 Merck & Co Recent Developments
5.13 Sanofi
5.13.1 Sanofi Profile
5.13.2 Sanofi Main Business
5.13.3 Sanofi Anti-tumor Drug Products, Services and Solutions
5.13.4 Sanofi Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.13.5 Sanofi Recent Developments
5.14 Bayer
5.14.1 Bayer Profile
5.14.2 Bayer Main Business
5.14.3 Bayer Anti-tumor Drug Products, Services and Solutions
5.14.4 Bayer Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.14.5 Bayer Recent Developments
5.15 Biogen Idec
5.15.1 Biogen Idec Profile
5.15.2 Biogen Idec Main Business
5.15.3 Biogen Idec Anti-tumor Drug Products, Services and Solutions
5.15.4 Biogen Idec Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.15.5 Biogen Idec Recent Developments
5.16 Eisai
5.16.1 Eisai Profile
5.16.2 Eisai Main Business
5.16.3 Eisai Anti-tumor Drug Products, Services and Solutions
5.16.4 Eisai Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.16.5 Eisai Recent Developments
5.17 Teva
5.17.1 Teva Profile
5.17.2 Teva Main Business
5.17.3 Teva Anti-tumor Drug Products, Services and Solutions
5.17.4 Teva Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.17.5 Teva Recent Developments
5.18 Otsuka
5.18.1 Otsuka Profile
5.18.2 Otsuka Main Business
5.18.3 Otsuka Anti-tumor Drug Products, Services and Solutions
5.18.4 Otsuka Anti-tumor Drug Revenue (US$ Million) & (2018-2023)
5.18.5 Otsuka Recent Developments
6 North America
6.1 North America Anti-tumor Drug Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Anti-tumor Drug Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Anti-tumor Drug Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Anti-tumor Drug Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Anti-tumor Drug Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Anti-tumor Drug Market Dynamics
11.1 Anti-tumor Drug Industry Trends
11.2 Anti-tumor Drug Market Drivers
11.3 Anti-tumor Drug Market Challenges
11.4 Anti-tumor Drug Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
